1 – 20 of 34
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Identification of plasma protein profiles associated with risk groups of prostate cancer patients.
(
- Contribution to journal › Article
- 2012
-
Mark
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
(
- Contribution to journal › Article
- 2010
-
Mark
Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
(
- Contribution to journal › Article
- 2008
-
Mark
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
(
- Contribution to journal › Article
-
Mark
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
(
- Contribution to journal › Article
- 2007
-
Mark
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
(
- Contribution to journal › Article
- 2006
-
Mark
Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C.
(
- Contribution to journal › Article
-
Mark
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
(
- Contribution to journal › Article
- 2005
-
Mark
Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
(
- Contribution to journal › Article
-
Mark
Macro/Nano-Structured Silicon as Solid Support for Antibody Arrays: Surface Design, Reproducibility, and Assay Characteristics Enabling Discovery of Kallikrein Gene Products for Prostate Disease Diagnostics
(
- Contribution to journal › Article
-
Mark
Reproducible porous silicon protein microarrays -chip manufacturing and application to clinical biomarkers
2005) 9th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2005 In Micro Total Analysis Systems - Proceedings of MicroTAS 2005 Conference: 9th International Conference on Miniaturized Systems for Chemistry and Life Sciences 1. p.826-828(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2004
-
Mark
Integrated selective enrichment target - a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases
(
- Contribution to journal › Article
-
Mark
Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio
(
- Contribution to journal › Article
- 2003
-
Mark
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer
(
- Contribution to journal › Article
-
Mark
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)
(
- Contribution to journal › Article
-
Mark
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
(
- Contribution to journal › Article
-
Mark
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
(
- Contribution to journal › Article
-
Mark
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
(
- Contribution to journal › Article
-
Mark
Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues
(
- Contribution to journal › Article